{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
NCT01927094: Phase 4 Interventional Completed Acute Diarrhea
(2012)
Source URL:
First approved in 2015
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT01686698: Phase 4 Interventional Completed Cirrhosis
(2013)
Source URL:
First approved in 2015
Source:
Kimchi Lactic Acid 1000 by Biogenicskorea Co., LTD
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT01686698: Phase 4 Interventional Completed Cirrhosis
(2013)
Source URL:
First approved in 2013
Source:
Fusion Plus by U.S. Pharmaceutical Corporation
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT04053790: Phase 4 Interventional Completed Irritable Bowel Syndrome With Diarrhea
(2019)
Source URL:
First approved in 2011
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03117322: Phase 4 Interventional Completed Cerebral Palsy
(2017)
Source URL:
First approved in 2011
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02054455: Phase 4 Interventional Completed Gastrointestinal Symptoms
(2012)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02462590: Phase 4 Interventional Completed Ventilator Associated Pneumonia
(2015)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT00849277: Phase 4 Interventional Completed Respiratory Tract Infections
(2006)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE